BIND Therapeutics: JMP Securities Healthcare Conference (BIND Therapeutics) - Jul 11, 2014 - "BIND-014 Phase 1: Well Tolerated and Promising Signs of Clinical Activity"; "Once Every 3-Week Schedule in Phase 1 Trial (N=28);" "Well tolerated with predictable and manageable toxicity"; "No new or unexpected toxicities observed"; "Maximum Tolerated Dose declared at 60mg/m2, dose-limiting toxicity is neutropenia"; "Traditional docetaxel toxicities observed generally at low frequency and grade"; "Clinical Activity: 1 CR (Cervical): 3 PR (CRPC, NSCLC, Hepatobiliary): 7 SD > 12 weeks (CRPC, NSCLC, GI, H/N)"
P1 data • Non Small Cell Lung Cancer • Oncology • Prostate Cancer
|